Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Drug Makers See Need To Catch Up In Biotechs

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers are attempting to catch up to their major rivals abroad by stepping up efforts to bring antibody and other bioengineered pharmaceuticals to market. U.S. and European companies have dominated the market for biotech drugs, but Takeda and other drug makers hope to close the gap. Takeda has applications pending in Japan for an antibody drug, while Eisai and Chugai market theirs, but they and other Japanese drug makers continue to lag. The smaller share of the world market usually means the drug makers also spend less on research. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel